Valiant Organics Limited (VALIANTORG) AI Stock Analysis

• Market Cap: ₹6.28B
• Dividend Yield: N/A
• Average Volume (3M): 2.15K
• Price to Earnings (P/E): 28.7
• Beta (1Y): 0.74
• Revenue Growth: 16.43%
• EPS Growth: N/A
• Country: IN
• Employees: 1,073
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): 1.30
• Shares Outstanding: 28,019,610
• 10 Day Avg. Volume: 2,085
• 30 Day Avg. Volume: 2,152
• PEG Ratio: 3.90
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 1.14
• P/FCF Ratio: 31.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ₹220.00 ▼(-21.43% Downside)
• Action: Reiterated Date: 11/21/25
• Date: Action: Reiterated 11/21/25

Valiant Organics Limited's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's high P/E ratio, despite financial challenges, suggests overvaluation. The absence of earnings call data and corporate events leaves the focus on the need for improved profitability and market sentiment.

Positive Factors

Balance sheet equity buffer

A reasonable equity ratio provides a durable capital cushion that supports operational continuity and creditor confidence. Over the next 2–6 months this equity base can absorb earnings volatility, improve borrowing terms, and sustain supplier relationships while the company works to restore profitability.

Diversified end-market exposure

Serving multiple downstream industries reduces single-market cyclicality and supports steadier demand. Structural exposure to agrochemicals, pharma and pigments gives recurring demand drivers and technical stickiness from custom intermediates, helping revenue stability and customer retention over medium term.

Modest revenue growth trend

Positive revenue growth indicates continued market traction for core products and capacity to expand sales, even if margins are weak. Over months this trend can underpin recovery efforts, provide operating leverage as costs are optimized, and signal enduring demand for intermediates.

Negative Factors

Declining profitability

Shifting from positive to negative net income and a negative profit margin is a structural risk: persistent losses erode equity, limit reinvestment, and impair pricing power. Unless margins sustainably recover, the company will struggle to fund growth or cover fixed costs over the coming months.

High leverage

Elevated debt relative to equity increases financial rigidity and sensitivity to interest costs. With declining equity, leverage constrains strategic options, raises refinancing risk, and reduces capacity for capex or R&D investment, weakening the company’s medium-term competitive positioning.

Weak and inconsistent cash generation

Declining operating cash flow and erratic free cash flow undermine the company’s ability to service debt, pay suppliers, and finance necessary maintenance or growth capex. Over a multi-month horizon this elevates liquidity risk and may force dilutive financing or asset curtailment.

Valiant Organics Limited Business Overview & Revenue Model

Company Description

Valiant Organics Limited, a chemical manufacturing company, manufactures and markets specialty chemicals in India. Its products include para chlorophenol; ortho chlorophenol; 2,4 di-chlorophenol; 2,4,6 tri- chlorophenol; 2,6 di-chlorophenol; and para nitroaniline. The company's products also comprise ortho chloro para nitro aniline, 6 acetyl OAPSA, OA acetanilide, and PA acetanilide; ortho anisidine, para anisidine, ortho toluidine, para toluidine, IPPCA, FI aniline, and meta chloro aniline; acids; para and ortho amino phenol; and ortho and para nitro anisole. Its products are primarily used as intermediates in agro chemicals, dyes, pigments, pharmaceuticals, cosmetics, specialty chemicals, polymer, and veterinary drugs. The company also exports its products to Europe, Asia, and the United States. Valiant Organics Limited was founded in 1984 and is based in Mumbai, India.

How the Company Makes Money

Valiant Organics generates revenue through several key streams, primarily by manufacturing and selling specialty chemicals and agrochemical products. The company's revenue model is based on direct sales to agricultural businesses, distributors, and other industrial clients. Additionally, Valiant Organiсs capitalizes on partnerships with agricultural firms and research institutions, which help in the development of new products and technologies. The company also leverages its expertise in sustainability to attract clients looking for eco-friendly solutions, thus enhancing its market position and revenue potential. Seasonal demand in the agricultural sector, alongside long-term supply contracts and strategic collaborations, further contribute to its earnings.

Valiant Organics Limited Financial Statement Overview

Summary

Valiant Organics Limited faces challenges with declining revenue and profitability, as well as inconsistent cash flow generation. While the balance sheet reflects a reasonable equity position, the high leverage and declining equity trend are concerning. The company needs to focus on improving profitability and stabilizing cash flows to enhance its financial health.

Income Statement

Valiant Organics Limited has experienced declining revenue over the past few years, with a significant decrease in net income from positive to negative territory. The company shows a negative net profit margin, indicating profitability issues. The gross profit margin has improved recently, but overall profitability remains weak with negative EBIT and EBITDA margins in the latest period.

Balance Sheet

The balance sheet presents a reasonable equity ratio, suggesting a solid asset base relative to liabilities. However, the debt-to-equity ratio indicates significant leverage, which poses potential financial risk. While stockholders' equity exceeds total debt, the declining trend in equity raises concerns about balance sheet robustness.

Cash Flow

The company shows a declining trend in operating cash flow, and free cash flow has been inconsistent, with recent periods showing a decrease. The free cash flow to net income ratio is concerning due to negative net income. Although there is some positive operating cash flow, the overall cash flow position is weak, with potential liquidity challenges.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	7.55B	7.19B	7.23B	10.52B	11.53B	7.55B
Gross Profit	2.74B	2.62B	470.01M	1.81B	2.17B	2.19B
EBITDA	713.53M	615.51M	425.75M	1.77B	2.12B	2.11B
Net Income	50.87M	-37.36M	-83.91M	881.21M	1.13B	1.15B
Balance Sheet
Total Assets	0.00	11.83B	12.48B	12.39B	11.92B	8.76B
Cash, Cash Equivalents and Short-Term Investments	76.45M	131.53M	71.02M	456.71M	499.47M	349.85M
Total Debt	0.00	2.49B	2.57B	2.74B	3.63B	2.09B
Total Liabilities	-7.25B	4.58B	5.19B	4.99B	5.43B	3.68B
Stockholders Equity	7.25B	7.25B	7.29B	6.89B	6.13B	5.02B
Cash Flow
Free Cash Flow	0.00	256.03M	90.70M	862.19M	-1.53B	-562.54M
Operating Cash Flow	0.00	564.32M	840.00M	2.38B	-307.47M	1.15B
Investing Cash Flow	0.00	-209.61M	-649.88M	-1.43B	-1.24B	-1.59B
Financing Cash Flow	0.00	-318.13M	-231.19M	-1.12B	1.67B	486.70M

Valiant Organics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 280.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTORG, the sentiment is Negative. The current price of 280 is above the 20-day moving average (MA) of 251.72, above the 50-day MA of 254.84, and below the 200-day MA of 329.43, indicating a bearish trend. The MACD of -6.82 indicates Positive momentum. The RSI at 31.13 is Neutral, neither overbought nor oversold. The STOCH value of 13.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VALIANTORG.

Valiant Organics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BHARATWIRE	76 Outperform	₹12.02B	15.68	―	―	8.45%	-14.27%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
EVERESTIND	49 Neutral	₹6.22B	-13.28	―	0.50%	-3.11%	-331.77%
DECCANCE	48 Neutral	₹10.08B	32.65	―	0.08%	-28.32%	93.44%
FAIRCHEMOR	47 Neutral	₹7.43B	319.68	―	1.07%	-22.10%	-85.56%
VALIANTORG	46 Neutral	₹6.28B	28.67	―	―	16.43%	―
HERANBA	44 Neutral	₹8.02B	-13.35	―	0.39%	―	―